SGLT2 inhibitors: A silver bullet?
September 20, 2021by Sean S. Hong Sodium glucose co-transporter-2 (SGLT2) inhibitors promote the kidneys to filter glucose out of the blood and excrete the glucose as waste. As a result, SGLT2 inhibitors are indicated to treat patients for type 2 diabetes as an alternative to insulin or metformin. Canagliflozin (Invokana®) was first... View Article